Aptamer Beacons As A Simple Solution-Based Diagnostic Platform

Molecular Aptamer Beacons are novel reagents capable of simple, solution-based detection and reporting of target concentration through a fluorescence-based readout.

This assay format has a number of advantages

Simple solution-based assay format – no complicated incubations, wash steps etc. are required
Field-based application using a simple hand-held reader
Readily developed into multiplexed assays using aptamers with […]

Aptamer Group February 2019

14th February 2019
This month:

Aptamers for therapeutic drug monitoring in plasma
Aptamer Group speaking at a premier aptamer conference
Interesting applications in portable quantitative aptasensors and  protease inhibitors

With lots of new data ongoing for multiple applications in the commercial and academic space, Aptamer Group would like to share with you information that may be of interest […]

Literature Review: Novel Aptamer Protease Inhibitors

13th February 2019
Serine proteases are enzymes that cleave peptide bonds in proteins, in which serine serves as the reactive amino acid at the enzyme’ active site. In humans, they are responsible for coordinating various physiological functions, including digestion, immune response, blood coagulation and reproduction (Hedstrom). The design and development of small molecule inhibitors of proteases have […]

Aptamers for Therapeutic Drug Monitoring in Plasma

5th February 2019
Aptamer Group recently collaborated with a commercial partner to develop aptamers to a variety of small molecule drugs and their active metabolites for biosensor based therapeutic drug monitoring.  Therapeutic drug monitoring (TDM) is the clinical practice of measuring drugs and their subsequent metabolites at designated intervals to understand concentration in a patient’s bloodstream […]

Cancer Biomarker Capture and Elution by Cell Specific Aptamers

15th January 2019

Aptamers have a great potential in cancer biomarker discovery via selection against cancer cells following counter selection against healthy cells. Aptamers were identified to bind to cancer specific biomarkers on cells and then subsequently isolated and analysed.

Prostate cancer cells were lysed and incubated with streptavidin magnetic beads pre-immobilized with a biotinylated single stranded […]

Aptamer Group Announces Agreement with AstraZeneca to Explore Next-Generation Drug Delivery Devices

7th January 2019
Aptamer Group today announced it has signed an agreement with AstraZeneca to explore the potential of using aptamer technology to target the kidney. The two-year agreement will give AstraZeneca use of Aptamer Group’s proprietary technology to explore the feasibility of developing the next generation of drug delivery vehicles, called Aptamer Drug Conjugates (ApDCs).

Aptamers […]

Aptamer Group December 2018

19th December 2018
This month:

Aptamer Group data on selective cell based biomarker aptamers
The year in review, from new product launches to company accolades
Interesting applications in international diagnostics and small molecule lateral flow assays

Novel Solutions – Biomarkers 
Aptamers specific to the same cell type at different stages within a disease cycle

No biomarker abundance restriction
Whole […]

Aptamer Group November 2018

29th November 2018.
This month:

Aptamer Group data on selective bind and elution reusability of aptamer  purification columns
Small molecule analysis webinar with Pall ForteBio BLI platform
Our CEO Today United Kingdom award
Interesting applications in antibiotic biosensors and ELISA antibody/aptamer pairs

Novel Solutions – Purification 
Reproducibility of aptamers that bind and release under defined conditions

Less expensive
Gentle […]

CEO Today Magazine Awards – Winners

3rd December 2018
Aptamer Group is proud to receive the CEO Today Magazine United Kingdom Awards for distinguished performance by our CEO and Founder Arron Tolley.

The award recognises, identifies and honours the most respected companies and their C-level executives operating within the United Kingdom today. Researchers at CEO Today determine the eligibility of the CEO/Executive based […]